Literature DB >> 23540710

Endophthalmitis isolates and antibiotic susceptibilities: a 10-year review of culture-proven cases.

Andrew M Schimel1, Darlene Miller, Harry W Flynn.   

Abstract

PURPOSE: To investigate the spectrum of organisms causing culture-proven endophthalmitis and their susceptibilities to commonly used antimicrobial agents over 10 years.
DESIGN: Retrospective, noncomparative, consecutive case series.
METHODS: Medical records were reviewed of all cases with culture-proven endophthalmitis at a single institution from 2002 through 2011. The outcome measures included all intravitreal isolates identified as well as antibiotic susceptibilities.
RESULTS: A total of 448 organisms were isolated during the study interval. The most common organisms identified were Staphylococcus epidermidis in 30.1% (135/448), Streptococcus viridians group in 10.9% (49/448), Staphylococcus aureus in 7.8% (35/448), Candida albicans in 5.8% (26/443), other coagulase-negative staphylococci in 6.0% (27/448), Propionibacterium acnes in 4.7% (21/448), and Pseudomonas aeruginosa in 3.1% (14/448). Overall, 327 (72.9%) of 448 isolates were gram-positive organisms, 48 (10.7%) of 448 isolates were gram-negative organisms, 71 (15.8%) of 448 isolates were fungi, and 2 (0.4%) of 448 isolates were viruses. For gram-positive organisms, susceptibilities were the following: vancomycin, 100%; gentamicin, 88.0%; sulfamethoxazole/trimethoprim, 77.5%; levofloxacin, 58.5%; oxacillin, 54.7%; ciprofloxacin, 51.0%; gatifloxacin, 51.0%; and moxifloxacin, 47.0%. For gram-negative organisms, susceptibilities were the following: ceftazidime, 100%; levofloxacin, 100%; ciprofloxacin, 95.0%; tobramycin, 90.6%; gentamicin, 80.6%; and sulfamethoxazole/trimethoprim, 59.4%.
CONCLUSIONS: In the current study, no single antibiotic provided coverage for all of the microbes isolated from eyes with endophthalmitis. Combination therapy generally is the recommendation as the initial empiric treatment of suspected bacterial endophthalmitis. Appropriate history and characteristic clinical features may guide the use of initial antifungal agents.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23540710     DOI: 10.1016/j.ajo.2013.01.027

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  37 in total

1.  Analysis of the Surface, Secreted, and Intracellular Proteome of Propionibacterium acnes.

Authors:  Yang Yu; Jackson Champer; Jenny Kim
Journal:  EuPA Open Proteom       Date:  2015-06-16

Review 2.  Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery.

Authors:  Emily W Gower; Kristina Lindsley; Samantha E Tulenko; Afshan A Nanji; Ilya Leyngold; Peter J McDonnell
Journal:  Cochrane Database Syst Rev       Date:  2017-02-13

3.  The Susceptibility of Bacterial Endophthalmitis Isolates to Vancomycin, Ceftazidime, and Amikacin: a 23 Year-Review.

Authors:  Shilpa Kodati; Andrew W Eller; Regis P Kowalski
Journal:  Ophthalmol Retina       Date:  2017 May-Jun

4.  Screening and characterization of Staphylococcus aureus from ophthalmology clinic surfaces: a proposed surveillance tool.

Authors:  Rachel E Reem; Joany Van Balen; Armando E Hoet; Colleen M Cebulla
Journal:  Am J Ophthalmol       Date:  2014-01-09       Impact factor: 5.258

5.  Effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injections.

Authors:  Mustafa Ataş; Burhan Başkan; Ayşe Ozköse; Fatma Mutlu Sarıgüzel; Süleyman Demircan; Emine Pangal
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

6.  Transferable Multidrug-Resistance Plasmid Carrying a Novel Macrolide-Clindamycin Resistance Gene, erm(50), in Cutibacterium acnes.

Authors:  Sae Aoki; Keisuke Nakase; Hidemasa Nakaminami; Takeaki Wajima; Nobukazu Hayashi; Norihisa Noguchi
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  Emerging Worldwide Antimicrobial Resistance, Antibiotic Stewardship and Alternative Intravitreal Agents for the Treatment of Endophthalmitis.

Authors:  Nidhi Relhan; Avinash Pathengay; Stephen G Schwartz; Harry W Flynn
Journal:  Retina       Date:  2017-05       Impact factor: 4.256

8.  Susceptibility of bacterial isolates to vancomycin and ceftazidime from patients with endophthalmitis: Is there a need to change the empirical therapy in suspected bacterial endophthalmitis?

Authors:  Ashok Kumar Reddy; Raja Rami Reddy; Muralidhar Rao Paruvelli; Srinivas Ambatipudi; Alka Rani; Sikander A K Lodhi; Juturi Maruthi Lokabhi Reddy; K Ramakanth Reddy; Niraj Pandey; Rituraj Videkar; Manish Kumar Sinha; Ajit Babu Majji; Nilanjana Deb-Jorder; Atul Kumar Sahu; Jyostna Myneni; Anina Abraham
Journal:  Int Ophthalmol       Date:  2014-11-11       Impact factor: 2.031

9.  Characterization of ocular methicillin-resistant Staphylococcus epidermidis isolates belonging predominantly to clonal complex 2 subcluster II.

Authors:  Paulo J M Bispo; Ana Luisa Hofling-Lima; Antonio C C Pignatari
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

10.  Is It Time to Abandon Subconjunctival Antibiotics following Pars Plana Vitrectomy?

Authors:  John W Hinkle; Nidhi Relhan; Harry W Flynn
Journal:  Retina       Date:  2018-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.